MCT - Mobile Cardiac Reporting
- Remote Monitoring
- Clinical Environments
- Health and Wellness
USA & EU CLEARANCE
The wearable patch is Class IIa medical devices and have received FDA clearance for sale in the US and regulatory approval (CE Mark) for distribution in the EU.
- 88% reduction in predictable codes.
- Vital signs changes seen 4 - 6 hours before cardiac arrest.
- Early detection of deterioration of condition in 12% of patients.
- Changes to vital signs were present prior to 75% of in-hospital cardiac arrest deaths.
In the largest randomized trial in the world of remote monitoring technologies involving 6191 patients from the UK results found –
- 45% reduction in mortality rates
- 20% reduction in emergency admissions
- 15% reduction in A&E visits
- 14% reduction in elective admissions
- 14% reduction in bed days
- 8% reduction in tariff costs
- Leading US hospitals
- NHS UK
- Global Pharma companies
- US Government Departments
- Humanitarian Agencies
Cutting edge medically approved wearable technology
The future of ECG remote monitoring is here today
Innovation: Our cutting edge wearable biosensor patch is self-adhesive sticking to the chest and provides high quality measurements of several physiological vital signs but for the MCT solution it focuses on providing near flawless and wireless ECG signal continuously for 5 days. This signal is delivered in real-time to our servers where dedicated and highly trained analysts review the data.
The small, discrete patch eliminates the need for chest straps, wrist bands, wires and recorders to be worn by the patient. It is easy to use and comfortable at home or on the go.
The Future is here today: No other device and solution can match our patch for real-time continuous ECG monitoring and accurate reporting. Similar devices are much bulkier and offer only retrospective ECG analysis after the device is mailed back to provider and the data is downloaded. This typically can take up to 30 days. With MCT (mobile cardiac telemetry), cardiac events can be reported and acted in real time.
You can order a 24 – 120 hour MCT study kit for your patients. Our package is supported by dedicated analysts who monitor each and every beat of the patients ECG. To assist our highly trained analysts, CorVitals has integrated highly sensitive (FDA approved) ECG analysis software which alerts our analysts to a significant pre-established change in rate, rhythm, ectopic or pause. They will then immediately alert the physician who prescribed the test
On completion of the MCT study, the prescribing physician is provided with full detailed ECG analysis report.